C5 and age-related macular degeneration: To date, intravenous eculizumab (manufactured by Alexion Pharmaceuticals, New Haven, CT, USA), a monoclonal antibody against C5, is the only systemic complement inhibitor to have completed a randomised controlled trial in AMD, and it failed to show any significant benefits in terms of anatomy or function in a randomised controlled trial for GA [235].